Company news

Recce Pharmaceuticals Ltd. news in 2026

Recce Pharmaceuticals Ltd.'s news releases, calls and decks from 2026, newest first.

View company

Options Prospectus

November 3, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 29, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 29, 2026

License and Commercialisation Agreement in AUS/NZ for R327G

October 21, 2026

License and Commercialisation Agreement in AUS/NZ for R327G

October 21, 2026

Independent Review of Indonesian Phase 3 R327G Trial Data

October 19, 2026

Independent Review of Indonesian Phase 3 R327G Trial Data

October 19, 2026

Amendments to Debt Facility with Avenue Capital Group

October 16, 2026

Amendments to Debt Facility with Avenue Capital Group

October 16, 2026

Appendix 4E and FY26 Annual Report

August 31, 2026

HREC Approves Comparator Study for Pivotal Phase 3 DFI

August 18, 2026

Vietnamese Patent Granted for RECCE Anti-Infectives

July 13, 2026

AUD $3.7M Income Tax Refund Received

June 30, 2026

Placement & SPP to raise $8 million

June 25, 2026

HREC Approval Accelerates Global Phase 3 DFI Strategy

June 21, 2026

Addendum to Recce Signs Middle East Licensing Term Sheet

May 27, 2026

Recce Signs Middle East Licensing Term Sheet

May 26, 2026

Brazil Patent Granted for RECCE Anti-Infectives

March 24, 2026

RCE Investor Webinar Presentation Deck

March 19, 2026

Appendix 4D and Interim Financial Report

February 27, 2026

Recce Enters Second U.S. Department of Defense R&D Agreement

February 1, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 30, 2026

AUD $5.3m R&D Rebate Received

January 13, 2026

Decks in 2026